[News] ESTRO 2024

May, 05, 2024 | Select Oncology Journal Articles

Speaking on behalf of researchers from 25 Spanish centres, Felipe Couñago (GenesisCare, Madrid, Spain) reported that moderate postoperative hypofractionated radiotherapy for patients with prostate cancer yields a good biochemical response, quality of life, and limited gastrointestinal and genitourinary toxicity. The non-randomised HYPORT-ES phase 2 trial recruited 407 patients and delivered 62·5 Gy in 2·5 Gy fractions via intensity-modulated radiotherapy or image-guided radiotherapy. Primary outcomes were acute and late toxicity.

For Additional News from OncWeekly – Your Front Row Seat To The Future of Cancer Care –




Sign up for our emails

Trusted insights straight to your inbox and get the latest updates from OncWeekly

Privacy Policy